Log in

603259 WuXi AppTec Co., Ltd. SSE · China

WuXi AppTec Co. (603259) news 603259 convertible notes news

Latest WuXi AppTec Co. news

We have not published a story on WuXi AppTec Co. yet. When there is news, it will appear here.

Questions about WuXi AppTec Co.

Has WuXi AppTec Co. sold convertible notes?

Our latest story on this, dated May 15, 2026: "WuXi AppTec agrees to issue RMB6,780 million convertible bonds". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of WuXi AppTec Co.?

WuXi AppTec Co., Ltd. trades under the ticker 603259 on SSE.

Where is WuXi AppTec Co. listed?

WuXi AppTec Co., Ltd. is listed on SSE. Our directory also records these other listings: BMV:2359/N; GETTEX:WX8; HKEX:2359; LS:A2PAJG; OTC:WUXAY; OTC:WUXIF; SET:WUXIAT80.

Which country or territory is WuXi AppTec Co. listed under?

Our directory records WuXi AppTec Co., Ltd. under China.

What does WuXi AppTec Co. do?

Our directory classifies WuXi AppTec Co., Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of WuXi AppTec Co.?

The ISIN recorded for WuXi AppTec Co., Ltd. is CNE1000031K4.

Does aibio.space cover WuXi AppTec Co.?

aibio.space lists WuXi AppTec Co., Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

What is the latest WuXi AppTec Co. (603259) stock news?

Our latest story on WuXi AppTec Co., dated May 15, 2026: "WuXi AppTec agrees to issue RMB6,780 million convertible bonds". WuXi AppTec signed a subscription agreement on May 14, 2026 for bonds with an initial conversion price of HK$153.00 per H share. Source.

Which companies are similar to WuXi AppTec Co.?

Companies in our directory listed in the same country and business area as WuXi AppTec Co.: Tuoxin Pharmaceutical Group Co., Hua Medicine, Harbin Pharmaceutical Group Co., BGM Group, Jiangsu Lianhuan Pharmaceutical Co., Shanghai Fosun Pharmaceutical (Group) Co..

How can I follow WuXi AppTec Co. (603259) news?

Press Follow on this page to add WuXi AppTec Co. to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming WuXi AppTec Co. so far, in Debt Financing.

Investor discussion: WuXi AppTec Co.

Members talk about WuXi AppTec Co. (603259). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open SSE:603259 on TradingView.

Listing details

WuXi AppTec Co., Ltd. is a public biotech or pharmaceutical company listed on SSE under the ticker 603259, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
WuXi AppTec Co., Ltd.
Ticker
603259
Listing
SSE
Country or territory
China
Business scope
Pharmaceuticals: Major
ISIN
CNE1000031K4
Other listed symbols
BMV:2359/N; GETTEX:WX8; HKEX:2359; LS:A2PAJG; OTC:WUXAY; OTC:WUXIF; SET:WUXIAT80
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.